Iovance Biotherapeutics (IOVA) Jefferies Global Healthcare Conference 2026 summary

Commercial performance and market outlook

• AMTAGVI launch is accelerating, with strong uptake in both academic and community centers, targeting over 110 authorized treatment centers in the U.S. and expanding internationally, including recent approval in Australia and pending approvals in the U.K., Switzerland, and Canada.

• Peak U.S. sales for AMTAGVI and Proleukin are projected to exceed $1 billion within the next few years, with the non-small cell lung cancer market being seven times larger than melanoma.

• 2024 revenue guidance is $350–$370 million, with Q2 AMTAGVI sales expected at $79–$81 million, and strong visibility into patient demand and manufacturing capacity.

• Manufacturing upgrades are complete, ensuring continuous supply and eliminating previous disruptions; gross margins are expected to improve toward a long-term target of 70%.

• Operating expenses have been reduced to about $100 million per quarter, with ongoing focus on financial discipline and efficiency as the business scales.

Clinical data and pipeline developments

• AMTAGVI demonstrates a 52% response rate in second-line melanoma, with long-term data suggesting about half of deep responders are functionally cured after 10 years.

• Real-world and clinical data support earlier treatment, with response rates dropping from 52% in second-line to 33% in third-line settings.

• The TILVANCE-301 study aims to confirm benefit in second-line and seek accelerated and full approvals in first-line melanoma, using ORR and PFS as key endpoints.

• Second-line non-small cell lung pivotal phase II is nearing full enrollment, with ORR and DOR as regulatory endpoints; accelerated approval is targeted for the second half of 2027.

• Recent phase II data in serous endometrial cancer and two sarcoma subtypes show high response rates (40–50%), with pivotal studies ongoing and potential for additional near-term approvals.

Competitive landscape and strategic positioning

• No near-term competition is expected for AMTAGVI; competitors face regulatory setbacks and lack comparable manufacturing scale or clinical durability.

• The company’s manufacturing facility can supply at least 5,000 patients annually, with potential for further expansion.

• Differentiation is driven by robust clinical outcomes, manufacturing scale, and a broad pipeline, including next-generation assets like IL-12 tethered TIL therapy and PD-1 knockout programs.

• The IL-12 tethered TIL program, recently cleared by the FDA for clinical entry, targets immunologically cold tumors and could significantly expand the addressable patient population.

• Financially, the company holds $320 million in cash (Q1), expected to fund operations into 2028, with a focus on achieving profitability through revenue growth, margin expansion, and cost control.